You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Estimated Costs of Prescription Opioid Analgesic Abuse in the United States in 2001: A Societal Perspective

Birnbaum, Howard G. PhD*; White, Alan G. PhD*; Reynolds, Jennifer L. BA*; Greenberg, Paul E. MS*; Zhang, Mingliang PhD; Vallow, Sue RPh, MBA, MA; Schein, Jeff R. DrPH, MPH; Katz, Nathaniel P. MD§

Clinical Journal of Pain:
doi: 10.1097/01.ajp.0000210915.80417.cf
Original Articles
Abstract

Objectives: This study estimates the costs to society of prescription opioid analgesic (RxO) abuse in the United States.

Methods: Costs associated with RxO abuse were grouped into healthcare, criminal justice, and workplace categories. Costs were estimated by either (1) a quantity method that multiplies the number of RxO abusers derived from various national surveys by the estimated per abuser cost, or (2) an apportionment method that starts with overall (ie, prescription and nonprescription) drug abuse costs for a cost component (eg, police protection) and apportions the share of costs based on the prevalence of RxO abuse relative to overall drug abuse. Medical costs in excess of those for otherwise similar nonabusers were based on an analysis of a large administrative claims database for an employed population using multivariate regression methods.

Results: A lower bound estimate of the costs of RxO abuse in the United States was $8.6 billion in 2001 (or $9.5 billion in 2005 dollars). Of this amount, $2.6 billion were healthcare costs, $1.4 billion were criminal justice costs, and $4.6 billion were workplace costs.

Conclusions: The costs of RxO abuse represent a substantial economic burden. Rising trends of RxO abuse suggest an escalating economic and public health burden in coming years in the United States, and potentially, elsewhere.

Author Information

*Analysis Group, Inc, Boston, MA

Health Economics and Pricing, Johnson and Johnson Pharmaceutical Services, Raritan, NJ

Outcomes Research, Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ

§Tufts University School of Medicine, Boston, MA; Analgesic Research, Newton, MA

Support by Johnson & Johnson Pharmaceutical Services, LLC, and Ortho-McNeil Janssen Scientific Affairs, LLC.

Reprints: Howard G. Birnbaum, Analysis Group, Inc, 111 Huntington Avenue, 10th Floor, Boston, MA 02199 (e-mail: hbirnbaum@analysisgroup.com).

Received for publication October 6, 2005; accepted May 10, 2006

© 2006 Lippincott Williams & Wilkins, Inc.